Drug-Drug Interaction (DDI) Study of Leramistat in Healthy Adult Subjects
A Phase 1, Open-label, 4-Part, Drug-Drug Interaction Study to Evaluate the Effects of Inhibition and Induction of CYP3A4 on the Pharmacokinetics of Leramistat, to Assess the Effect of Leramistat on the Pharmacokinetics of Simvastatin, and to Evaluate the Pharmacokinetic Interaction Between Leramistat and Upadacitinib (RINVOQ®) in Healthy Adult Subjects
Modern Biosciences Ltd
48 participants
Apr 8, 2024
INTERVENTIONAL
Conditions
Summary
A DDI study consisting of 4 parts conducted as an open label, fixed sequence study in healthy adult subjects.
Eligibility
Inclusion Criteria1
- Healthy, adult, male or female of non childbearing potential 18 to 55 years of age.
Exclusion Criteria2
- History or presence of clinically significant medical or psychiatric condition or disease in the opinion of the PI or designee.
- History of any illness that, in the opinion of the PI or designee, might confound the results of the study or poses an additional risk to the subject by their participation in the study.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Oral capsule
Oral capsule
Oral capsule
Oral capsule
Oral Capsule
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06379958